Please sign in to follow a disease.
ALK+ non-small-cell lung carcinoma
Clinical trials for ALK+ non-small-cell lung carcinoma explained in plain language.
Never miss a new study
Get alerted when new ALK+ non-small-cell lung carcinoma trials appear
Sign up with your email to follow new studies for ALK+ non-small-cell lung carcinoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Can a new drug combo outsmart resistant lung cancer?
Disease control Recruiting nowThis trial is testing whether adding an experimental drug called NXP900 to the standard treatment lorlatinib can help people with advanced ALK-positive non-small cell lung cancer. The study includes adults who have already been treated with lorlatinib and whose cancer has not bee…
Matched conditions: ALK+ NON-SMALL-CELL LUNG CARCINOMA
Phase 1 • Sponsor: Nuvectis Pharma, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Real-World check: does lorlatinib work for ALK lung cancer?
Disease control Recruiting nowThis study looks at how effective and safe the drug lorlatinib is for people with a specific type of lung cancer (ALK-positive non-small cell lung cancer) who have not had treatment before. Researchers will follow 90 patients in French clinics to see how long they live without th…
Matched conditions: ALK+ NON-SMALL-CELL LUNG CARCINOMA
Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC